{"schemaVersion":"peptidescanner-evidence-object/v1","objectId":"story:pubmed-pmid-41260682-elamipretide:v1","objectPathId":"pubmed-pmid-41260682-elamipretide-v1","kind":"story-version","urls":{"story":"https://peptidescanner.com/stories/pubmed-pmid-41260682-elamipretide/","json":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41260682-elamipretide-v1.json","markdown":"https://peptidescanner.com/evidence/v1/objects/pubmed-pmid-41260682-elamipretide-v1.md"},"story":{"slug":"pubmed-pmid-41260682-elamipretide","version":1,"domain":"Literature metadata","dateInSource":"2026-01-14","sourceCheckedAt":"2026-07-30","publishedAt":"2026-08-13","peptideSlugs":["elamipretide"],"peptides":[{"slug":"elamipretide","url":"https://peptidescanner.com/peptides/elamipretide/"}]},"claims":[{"id":"headline","text":"Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval.","sourceIds":["pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa"]},{"id":"summary","text":"PubMed lists PMID 41260682 in Drug discoveries & therapeutics as Letter, with publication-date metadata of 2025-11-20 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa"]},{"id":"paragraph-1","text":"PubMed lists PMID 41260682 in Drug discoveries & therapeutics as Letter, with publication-date metadata of 2025-11-20 (day precision). PeptideScanner associated the retained record with the identity slug elamipretide. These fields reproduce attributed bibliographic metadata and do not summarize or endorse the article's findings.","sourceIds":["pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa"]},{"id":"paragraph-2","text":"This page reproduces bounded bibliographic metadata attributed to PubMed. Its title and publication details are source metadata, not PeptideScanner's endorsement or an assertion of safety, efficacy, or scientific truth.","sourceIds":["pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa"]}],"sources":[{"id":"pubmed-observation-pmid-41260682-2026-01-14-85a850a90afa","name":"PubMed","sourceClass":"A","title":"Elamipretide: The first cardiolipin-directed mitochondrial therapeutic for Barth syndrome approved under accelerated approval. · retained source version 1:2026-01-14:current:85a850a90afaf120fd282509822376f12f18ab63e6a893db5979cdc1097c8420","url":"https://pubmed.ncbi.nlm.nih.gov/41260682/"}],"correction":{"state":"none"},"boundaries":{"scope":"selected-public-evidence-only","reporting":"PeptideScanner reproduces bounded bibliographic metadata attributed to PubMed. It does not summarize or endorse the article's findings.","unknowns":["Sources outside the selected public PeptideScanner bundle may exist and are not represented by this object.","This object does not determine whether cited records agree, corroborate one another, or establish scientific truth.","This object does not determine safety, efficacy, causality, or suitability for any person."],"methodologyUrl":"https://peptidescanner.com/methodology/","medicalDisclaimerUrl":"https://peptidescanner.com/medical-disclaimer/"},"commitments":{"publicationLedgerSha256":"5ce95878434f576f03c953a1981961e47a05c42d5c55676c70caeed8c6bd6dbe","tierARecordSha256":"b7331be10633fded4dd336fe283a679041f1569c2d653e74f82f701a978b4239"},"integrity":{"algorithm":"sha256","contentSha256":"4369c10784e234e883b5398ec0aed0e276bcebcd2c4dc4318f02e3e7159a3107"}}